Table 1:
Characteristics of study participants in the discovery NCI and validation DBMT sets
| Discovery NCI Total, N=404 | Validation DBMT Total, N=1245 | P-value | |
|---|---|---|---|
| N (%) | |||
| Patient Age | 0.70 | ||
| <20 | 73 (18.07) | 254 (20.40) | |
| 20–<40 | 140 (34.65) | 420 (33.73) | |
| 40–50 | 90 (22.28) | 294 (23.61) | |
| 50+ | 101 (25.00) | 277 (22.25) | |
| Male Gender | 222 (54.95) | 689 (55.34) | 0.93 |
| Patient Race | 0.68 | ||
| Caucasian | 374 (92.57) | 1157 (92.93) | |
| African American | 12 (2.97) | 28 (2.25) | |
| Other | 18 (4.46) | 60 (4.82) | |
| Donor Age | 0.08 | ||
| 18–30 | 169 (41.94) | 463 (37.19) | |
| 31–<50 | 203 (50.37) | 705 (56.63) | |
| 50+ | 31 (7.69) | 77 (6.18) | |
| Donor Race | 0.33 | ||
| Caucasian | 361 (89.36) | 1084 (87.07) | |
| African American | 10 (2.47) | 28 (2.25) | |
| Other/unknown | 33 (8.17) | 133 (10.68) | |
| Disease Subtype | 0.65 | ||
| AML | 263 (65.10) | 793 (63.69) | |
| ALL | 141 (34.90) | 452 (36.31) | |
| Disease status at HCT | <0.001 | ||
| 1st complete remission | 253 (62.62) | 406 (32.61) | |
| 2nd complete remission | 151 (37.38) | 396 (31.81) | |
| Not in remission/advanced disease | 0 (0) | 463 (37.19) | |
| Recipient-donor CMV Match | 0.34 | ||
| Both negative | 131 (32.43) | 342 (27.47) | |
| Donor negative-recipient positive | 143 (35.40) | 426 (34.22) | |
| Donor positive-recipient negative | 55 (13.61) | 181 (14.54) | |
| Both positive | 75 (18.56) | 259 (20.80) | |
| Karnofsky Score | 0.001 | ||
| <90 | 88 (21.78) | 355 (28.51) | |
| 90–100 | 285 (70.54) | 755 (60.64) | |
| Missing | 31 (7.67) | 135 (10.84) | |
| Graft Type | <0.001 | ||
| Bone marrow | 129 (31.93) | 596 (47.87) | |
| Peripheral blood | 275 (68.07) | 649 (52.13) | |
| Use of Total Body Irradiation | 206 (50.99) | 761 (61.12) | <0.001 |
| GVHD Prophylaxis | <0.001 | ||
| Tacrolimus-based | 313 (77.48) | 772 (62.0) | |
| Cyclosporine-based | 91 (22.52) | 392 (31.49) | |
| Other | 0 (0) | 81 (6.51) | |
| Year of HCT | <0.001 | ||
| 2000–2003 | 0 (0) | 424 (34.06) | |
| 2004–2006 | 230 (56.93) | 532 (42.73) | |
| 2007–2008 | 174 (43.07) | 289 (23.21) | |
| Donor IFNL4 genotype | 0.88 | ||
| IFNL4-Null | 177 (43.81) | 556 (44.66) | |
| 1 copy IFNL4-positive | 179 (44.31) | 535 (42.97) | |
| 2 copies IFNL4-positive | 48 (11.88) | 154 (12.37) | |
| Recipient IFNL4 genotype* | 0.32 | ||
| IFNL4-Null | 156 (49.37) | 550 (44.90) | |
| 1 copy IFNL4-positive | 123 (38.92) | 531 (43.35) | |
| 2 copies IFNL4-positive | 37 (11.71) | 144 (11.76) | |
| Donor -rs117648444 genotype | 0.71 | ||
| G/G | 328 (81.38) | 1019 (82.11) | |
| G/A | 70 (17.36) | 212 (17.08) | |
| A/A | 5 (1.24) | 10 (0.81) | |
| Donor IFN-λ4 protein status | 0.91 | ||
| IFN-λ4-Null | 177 (43.92) | 556 (44.80) | |
| IFN-λ4-Weak | 56 (13.89) | 163 (13.13) | |
| IFN-λ4-Strong | 170 (42.18) | 522 (42.06) | |
*
based on non-overlapping 316 recipients from the discovery NCI set and 1225 recipients from the DBMT validation set with genotype information for rs368234815 in NCI set and rs12979860 in DBMT.